The Best Biotech Stocks to Buy in 2026

The article is broadly constructive on CRISPR Therapeutics and Vertex Pharmaceuticals, highlighting near-term catalysts including CRISPR's second-half data readouts for CTX611 and CTX310 and Vertex's povetacicept regulatory filing, with potential U.S. approval by year-end. CRISPR has $2.4 billion in cash and equivalents versus a roughly $5 billion market cap, supporting its pipeline execution. Vertex is emphasized for continued CF dominance and a growing non-CF portfolio, while the piece is ultimately framed as opinionated stock-picking rather than new company-specific financial results.

Analysis

The market is rewarding credible platform biotech again, but the important signal here is not “innovation wins” so much as “balance-sheet-backed optionality is being re-rated.” CRSP and VRTX both have enough capital and/or cash-generating core businesses to fund multiple shots on goal, which reduces the classic biotech financing overhang and makes clinical milestones more likely to be monetized rather than diluted away. That dynamic should keep quality growth biotech bid even if broader small-cap sentiment softens.

Second-order, VRTX is becoming a diversification story more than a single-asset story: the more its non-CF pipeline de-risks, the less the market has to model it as a mature monopoly with a shrinking terminal growth rate. That matters because it can rerate from a “cash cow” multiple to a “durable compounder” multiple if the new launches stack. CRSP, by contrast, is a higher-volatility catalyst vehicle: its pipeline readouts are binary, but positive data would create scarcity value around true in-vivo editing exposure, which the public market still values as a premium platform asset.

The contrarian view is that the current enthusiasm may be pulling forward multiple expansion before the data window hits. In the next 3-6 months, the sector is likely to trade more on headline risk than on fundamentals, so the asymmetric setup is not simply long biotech; it is long names with multiple catalysts and low financing risk, while shorting weaker peers that need capital or lack near-term readouts. The biggest reversal risk is a single clinical miss or regulatory delay in the second half, which would likely compress sentiment across the group faster than company-specific fundamentals would justify.

Key Decisions for Investors

• Long VRTX into the next 3-6 months as a quality-growth biotech compounder; favor pullbacks over strength because the market is likely underestimating how much multiple expansion follows pipeline de-risking.
• Long CRSP as a catalyst-driven beta-to-data name, but size smaller than VRTX; best entry is pre-readout when implied disappointment is cheapest relative to upside from a positive platform validation.
• Pair trade: long VRTX / short a lower-quality, cash-burning biotech with no near-term catalysts; the trade isolates balance-sheet strength and reduces sector beta while preserving upside from clinical execution.
• For event-driven accounts, use call spreads on CRSP into second-half readouts to define downside; the setup is favorable if data are positive, but the stock can gap hard on any miss.
• Watch for a sectorwide fade after catalyst dates; if both names rally into events, trim into strength because biotech often gives back 20-30% of event-premium once uncertainty clears.